<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01874743</url>
  </required_header>
  <id_info>
    <org_study_id>IMEA 043 CESAR</org_study_id>
    <nct_id>NCT01874743</nct_id>
  </id_info>
  <brief_title>Rosuvastatin to Decrease Residual Immune Activation in HIV Infection</brief_title>
  <acronym>CESAR</acronym>
  <official_title>Pilot Study of the Impact of Rosuvastatin Administration on Residual Chronic Immune Activation Under Antiretroviral Therapy: CESAR (Crestor En Sus Des AntiRétroviraux)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sidaction</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participating countries: France Objectives Principal objective To evaluate, in HIV-1 infected
      patients receiving effective antiretroviral therapy, the effect of the addition of
      Rosuvastatin (dose of 20mg/day) for 3 months, on CD8 T cell activation as assessed by the
      proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR
      Secondary objectives To evaluate the effect of Rosuvastatin administration on residual CD4
      and CD8 T cell activation To evaluate the effect of Rosuvastatin administration on the main
      serum soluble biomarkers of activation (CRP- HS, D-dimers, IL-6 and soluble CD14) To evaluate
      the effect of Rosuvastatin administration on CD4 T-cell count and on the CD4/CD8 T-cell ratio
      To study the relationship between the level of immune activation and the level of residual
      HIV replication in plasma To study the effect of Rosuvastatin administration on lipid
      profiles and the correlation between the HDL cholesterol and the CD4/CD8 T-cell ratio To
      evaluate the tolerance of Rosuvastatin at the dose of 20 mg/day
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Methodology Phase II pilot study; open-label; non comparative, bicentric, on-off design

      Estimated enrolment 40 subjects

      Outcomes Primary outcome :

      • Variation at month 3 in the proportion of CD8 T lymphocytes co-expressing CD38 and HLA-DR

      Secondary outcomes :

        -  Evolution of plasma/serum levels of CRP-HS, IL-6, soluble CD14 between baseline and
           month 3 and between month 3 and month 6

        -  Evolution of markers of CD4 T-cell activation (HLA-DR, Ki67) and CD8 T-cell activation
           (CD38, HLA-DR, Ki67) between baseline and month 3 and between month 3 and month 6 and
           evolution of the CD4/CD8 ratio between baseline and month 3 and between month 3 and
           month 6

        -  Evolution of CD4 T-cell count between baseline and month 3

        -  Evolution of HDL and LDL cholesterol between baseline and month 3 and between month 3
           and month 6

        -  Relationship between HDL cholesterol and CD4/CD8 ratio at baseline, month 3 and month 6

        -  Relationship between the levels of T-cell activation and of plasma HIV-RNA levels at a
           detection level of 3 copies/mL

        -  Adverse events grade &gt; 2 Eligibility Inclusion criteria

        -  HIV-infected patients receiving a combination of antiretroviral therapy for at least 24
           months, unchanged since at least 18 months, exhibiting plasma HIV-RNA level below 20
           copies and circulating CD4 T cell count below 500/mm3

        -  No indication for a treatment with statins (LDL cholesterol &lt; 4.1 mmol/L under stable
           diet).

      Non-inclusion criteria

        -  Patients receiving Maraviroc

        -  Patients receiving immune suppressing drugs

        -  Ongoing opportunistic, bacterial or viral infection

        -  CRP ≥ 10 mg/mL

        -  Co-infection with HCV (except if HCV cure), chronic HBV infection with active
           replication of HBV

        -  Indication for a treatment with statins

        -  Pregnancy

        -  CPK &gt; 3x Normal values

        -  ALT or AST &gt; 2x Normal values

        -  TG &gt; 4 mmol/L

        -  DFG &lt; 60 mL /min/1.73 m2

        -  Personal or familial history of genetic muscular disease

        -  History of muscular or hepatic toxicity with a statin or a fibrate

        -  Liver disease (TP &lt; 70%).

        -  Hypothyroidism

        -  Concomitant treatment with : Kétoconazole, Itraconazole, Ciclosporine, Erythromycine,
           Cimétidine, Quinidine, Diltiazem, Vérapamil, systemic corticosteroids, Phénobarbital,
           Phénytoïne, Carbamazépine, Rifampicine, Lansoprazole

        -  Vaccination during the study

      Intervention Rosuvastatin (20 mg/d per os) Intervention duration: 3 months Follow-up for 3
      additional months

      Statistical methods Bilateral Two-sided paired Wilcoxon to analyze the variation in the
      proportion of CD8 T lymphocytes that co-express CD38 and HLA-DR at month 3 (primary outcome).

      The evolution of parameters of interest between 2 visits will also be analyzed using
      bilateral two-sided paired Wilcoxon test. Statistical significance will be considered for p&lt;
      0.05.

      Substudies

      Estimated planning or Study / Trial timetable Trial/study start date: April 2012 Enrolment
      period: 12 months Subject participation duration: 6 months Total trial/study duration: 18
      months Estimated study/trial completion date: October 2013 [default date: date of last
      follow-up of last included patient, else justify the chosen date: date of &quot;gel de la base de
      données&quot;, date of end of substudies analyses (think to delay for sampling transport, duration
      of technical analyses)]

      Study / Trial design Phase II open-label pilot bicentric non comparative study. Patients
      eligible will receive Rosuvastatin for 3 months while continuing antiretroviral therapy.
      Patients will be followed-up 3 additional months after stopping the study drug (on-off
      design)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2012</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">September 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>CD8 T cell activation</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate, in HIV-1 infected patients receiving effective antiretroviral therapy, the effect of the addition of Rosuvastatin (dose of 20mg/day) for 3 months, on CD8 T cell activation as assessed by the proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Coexpress activation markers</measure>
    <time_frame>6 months</time_frame>
    <description>proportion of peripheral CD8 T cells that co-express the activation markers CD38 and HLA-DR</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rosuvastatin administration (on and off)on biomarkers activation</measure>
    <time_frame>6 months</time_frame>
    <description>• Changes from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in levels of CRP-HS, IL-6, soluble CD14 Changes from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in the proportion of CD4 T cells expressing HLA-DR or Ki67 activation markers and in the proportion of CD8 T cells expressing HLA-DR and/or CD38 or Ki67 activation marker</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relationship between the levels of T-cell activation and of plasma HIV-RNA (ultrasensible measure)</measure>
    <time_frame>6 months</time_frame>
    <description>• Relationship between the levels of T-cell activation and of plasma HIV-RNA levels at a detection level of 3 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CD4 T-cell count and on the CD4/CD8 T-cell ratio</measure>
    <time_frame>6 months</time_frame>
    <description>Changes in CD4 T-cell count between baseline and month 3 •
Changes in the CD4/CD8 ratio between baseline and month 3 and between month 3 and month 6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipids profiles on and off rosuvastatine association</measure>
    <time_frame>6 months</time_frame>
    <description>• Changes from baseline to month 3 (on rosuvastatin) and from month 3 to month 6 (off rosuvastatin) in levels of HDL and LDL cholesterol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance of Rosuvastatine</measure>
    <time_frame>6 months</time_frame>
    <description>To evaluate the tolerance of Rosuvastatin at the dose of 20 mg/day (Number of patients with adverse events grade &gt; 2)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Rosuvastatine 20 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosuvastatin 20 mg/day, once a day during 3 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin 20 mg/day</intervention_name>
    <description>All patients must take 20mg/day of rosavastatin during 3 months</description>
    <arm_group_label>Rosuvastatine 20 mg</arm_group_label>
    <other_name>Crestor ,(ZD 4522)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-infected patients receiving a combination of antiretroviral therapy for at least
             24 months, unchanged since at least 18 months, exhibiting plasma HIV-RNA level below
             20 copies and circulating CD4 T cell count below 500/mm3

          -  No indication for a treatment with statins (LDL cholesterol &lt; 4.1 mmol/L under stable
             diet).

        Exclusion Criteria:

          -  Patients receiving Maraviroc

          -  Patients receiving immune suppressing drugs

          -  Ongoing opportunistic, bacterial or viral infection

          -  CRP ≥ 10 mg/mL

          -  Co-infection with HCV (except if HCV cure), chronic HBV infection with active
             replication of HBV

          -  Indication for a treatment with statins

          -  Pregnancy

          -  CPK &gt; 3x Normal values

          -  ALT or AST &gt; 2x Normal values

          -  TG &gt; 4 mmol/L

          -  DFG &lt; 60 mL /min/1.73 m2

          -  Personal or familial history of genetic muscular disease

          -  History of muscular or hepatic toxicity with a statin or a fibrate

          -  Liver disease (TP &lt; 70%).

          -  Hypothyroidism

          -  Concomitant treatment with : Kétoconazole, Itraconazole, Ciclosporine, Erythromycine,
             Cimétidine, Quinidine, Diltiazem, Vérapamil, systemic corticosteroids, Phénobarbital,
             Phénytoïne, Carbamazépine, Rifampicine, Lansoprazole

          -  Vaccination during the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laurence Weiss, PH,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HEGP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laurence Weiss, PH,MD</last_name>
    <phone>56093299</phone>
    <phone_ext>+331</phone_ext>
    <email>laurence.weiss@egp.aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Antoine Hospital</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>pauline Campa, MD</last_name>
      <phone>49283044</phone>
      <phone_ext>+331</phone_ext>
      <email>pauline.campa@sat.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Pierre-Marie Girard, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>HEGP</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laurence Weiss, PHD,MD</last_name>
      <phone>56093299</phone>
      <phone_ext>+331</phone_ext>
      <email>laurence.weiss@egp.aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Laurence Weiss, PHD,MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 26, 2012</study_first_submitted>
  <study_first_submitted_qc>June 7, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2013</study_first_posted>
  <last_update_submitted>June 11, 2013</last_update_submitted>
  <last_update_submitted_qc>June 11, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 12, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV,</keyword>
  <keyword>Rosuvastatine,</keyword>
  <keyword>Antiretroviral therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

